Drug Control Act; Schedule I; Schedule IV.
HB1587 updates Virginia’s Drug Control Act by amending the state’s Schedule I and Schedule IV controlled-substances lists. The bill adds a large number of specific synthetic opioids, fentanyl analogs, nitazenes, hallucinogens, stimulants, benzodiazepines, sedatives, and synthetic cannabinoids to the schedules, and it also captures related salts, isomers, and certain chemical variants where applicable. In practical terms, the measure is aimed at keeping Virginia’s controlled-substance lists current with emerging designer drugs and newly identified abuse-prone compounds.
The Schedule I changes focus heavily on high-risk illicit substances and analogs, including many fentanyl derivatives, nitazenes, cathinones, dissociatives, hallucinogens, and synthetic cannabinoid compounds. The Schedule IV changes add or clarify lower-schedule depressants and other drugs with recognized abuse potential, including several benzodiazepines, sleep medications, stimulants, and certain narcotic drugs. The bill also includes a standard provision stating that the act may increase periods of imprisonment or commitment, though the fiscal note estimates no additional cost for adult incarceration and an indeterminate impact for juvenile commitments.
HB1587 expands the list of controlled substances under Virginia law by amending Code of Virginia §§ 54.1-3446 and 54.1-3452. This broadens the legal reach of the Drug Control Act to cover newly named substances and chemical families, which can affect criminal enforcement, prosecution, prescribing, manufacturing, distribution, and possession offenses tied to Schedule I and Schedule IV drugs. The bill also signals that violations could lead to additional incarceration or juvenile commitment exposure, although the fiscal impact is estimated as minimal for adult corrections.
The bill appears to have received overwhelmingly favorable support. It passed the House and Senate unanimously, and committee votes were also unanimous, indicating broad bipartisan agreement that updating the controlled-substances schedules was necessary. The lack of recorded opposition suggests the measure was viewed as a routine but important public-safety and drug-enforcement update rather than a controversial policy change.
There is little evidence of substantive contention in the available record, as no committee transcript excerpts were provided and every recorded vote was unanimous. The main policy issue implicit in the bill is the breadth of the scheduling updates: it sweeps in many specific compounds and chemical classes, which can raise concerns about overbreadth, future-proofing, and the impact on criminal penalties and enforcement discretion. However, no legislator or stakeholder opposition is reflected in the voting history provided.